SCYNEXIS INC (SCYX)
US8112922005 - Common Stock
Taking everything into account, SCYX scores 5 out of 10 in our fundamental rating. SCYX was compared to 197 industry peers in the Pharmaceuticals industry. SCYX has an average financial health and profitability rating. SCYX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
SCYX had positive earnings in the past year.
SCYX had a positive operating cash flow in the past year.
SCYX had negative earnings in 4 of the past 5 years.
In the past 5 years SCYX reported 4 times negative operating cash flow.
1.2 Ratios
SCYX's Return On Assets of 85.68% is amongst the best of the industry. SCYX outperforms 99.49% of its industry peers.
SCYX's Return On Equity of 136.73% is amongst the best of the industry. SCYX outperforms 99.49% of its industry peers.
SCYX's Return On Invested Capital of 56.46% is amongst the best of the industry. SCYX outperforms 98.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 85.68% | ||
| ROE | 136.73% | ||
| ROIC | 56.46% |
ROA(3y)-15.59%
ROA(5y)-38.9%
ROE(3y)-650.17%
ROE(5y)-521.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SCYX has a better Profit Margin (72.13%) than 98.46% of its industry peers.
Looking at the Operating Margin, with a value of 52.56%, SCYX belongs to the top of the industry, outperforming 98.97% of the companies in the same industry.
The Gross Margin of SCYX (88.91%) is better than 91.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 52.56% | ||
| PM (TTM) | 72.13% | ||
| GM | 88.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SCYX is creating value.
The number of shares outstanding for SCYX has been increased compared to 1 year ago.
Compared to 5 years ago, SCYX has more shares outstanding
SCYX has a better debt/assets ratio than last year.
2.2 Solvency
SCYX has an Altman-Z score of 1.04. This is a bad value and indicates that SCYX is not financially healthy and even has some risk of bankruptcy.
SCYX has a Altman-Z score (1.04) which is in line with its industry peers.
The Debt to FCF ratio of SCYX is 0.17, which is an excellent value as it means it would take SCYX, only 0.17 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.17, SCYX belongs to the top of the industry, outperforming 97.44% of the companies in the same industry.
SCYX has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
SCYX has a Debt to Equity ratio of 0.17. This is comparable to the rest of the industry: SCYX outperforms 44.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 0.17 | ||
| Altman-Z | 1.04 |
ROIC/WACC6.03
WACC9.37%
2.3 Liquidity
A Current Ratio of 3.72 indicates that SCYX has no problem at all paying its short term obligations.
SCYX has a Current ratio of 3.72. This is comparable to the rest of the industry: SCYX outperforms 55.90% of its industry peers.
A Quick Ratio of 3.72 indicates that SCYX has no problem at all paying its short term obligations.
SCYX has a Quick ratio of 3.72. This is comparable to the rest of the industry: SCYX outperforms 58.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
SCYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 201.49%, which is quite impressive.
SCYX shows a strong growth in Revenue. In the last year, the Revenue has grown by 2454.00%.
The Revenue has been growing by 251.82% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)201.49%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q101.41%
Revenue 1Y (TTM)2454%
Revenue growth 3YN/A
Revenue growth 5Y251.82%
Revenue growth Q2Q21.5%
3.2 Future
SCYX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -13.91% yearly.
Based on estimates for the next years, SCYX will show a very negative growth in Revenue. The Revenue will decrease by -10.49% on average per year.
EPS Next Y-113.91%
EPS Next 2Y-53.05%
EPS Next 3Y-10.64%
EPS Next 5Y-13.91%
Revenue Next Year-74.22%
Revenue Next 2Y-69.01%
Revenue Next 3Y-8.51%
Revenue Next 5Y-10.49%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 1.36, which indicates a rather cheap valuation of SCYX.
Based on the Price/Earnings ratio, SCYX is valued cheaper than 99.49% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.15, SCYX is valued rather cheaply.
SCYX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.36 | ||
| Fwd PE | N/A |
4.2 Price Multiples
100.00% of the companies in the same industry are more expensive than SCYX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1.39 | ||
| EV/EBITDA | -0.46 |
4.3 Compensation for Growth
A cheap valuation may be justified as SCYX's earnings are expected to decrease with -10.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-53.05%
EPS Next 3Y-10.64%
5. Dividend
5.1 Amount
SCYX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SCYNEXIS INC
NASDAQ:SCYX (5/17/2024, 7:25:33 PM)
After market: 2.6559 -0.11 (-4.12%)2.77
+0.36 (+14.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap104.65M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.36 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 85.68% | ||
| ROE | 136.73% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 52.56% | ||
| PM (TTM) | 72.13% | ||
| GM | 88.91% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)201.49%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-113.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)2454%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y